title: Use of everolimus in de novo renal recipients: initial experience in the Greek population.
abstract: Although everolimus has proven to be as clinically efficacious as mycophenolate mofetil (MMF), there are reports that proliferation signal inhibitors are associated with poor tolerability. This study reported the experience of a Greek transplant center using either everolimus or MMF in de novo renal transplant recipients. In this retrospective study, a cohort of 40 patients who received everolimus after renal transplant was matched for 10 descriptive parameters with a cohort of another 40 patients who received MMF. The primary endpoint was renal function measured by creatinine and its clearance as well as wound dehiscence and opportunistic infections. The mean creatinine clearance at month 3 was 61.03 +/- 16.99 mL/min versus 60.99 +/- 8.03 for living related recipients on everolimus versus MMF, respectively. The mean creatinine clearance at month 3 was 71.24 +/- 12.61 and 62.61 +/- 20.24 mL/min for cadaveric recipients on everolimus versus MMF, respectively. In addition, the incidence of wound dehiscence was 33.34% versus 3.92% and the incidence of cytomegalovirus infection, 8.33% versus 17.64% for the same two groups, respectively.
authors.affiliation: Organ Transplant Unit, Hippokration General Hospital, Thessaloniki, Hellas. vaspap@med.auth.gr
authors.forename: V
authors.initials: V
authors.lastname: Papanikolaou
authors.forename: D
authors.initials: D
authors.lastname: Vrochides
authors.forename: P
authors.initials: P
authors.lastname: Margari
authors.forename: G
authors.initials: G
authors.lastname: Imvrios
authors.forename: A
authors.initials: A
authors.lastname: Papagiannis
authors.forename: D
authors.initials: D
authors.lastname: Giakoustidis
authors.forename: I
authors.initials: I
authors.lastname: Fouzas
authors.forename: N
authors.initials: N
authors.lastname: Antoniadis
authors.forename: N
authors.initials: N
authors.lastname: Ouzounidis
authors.forename: A
authors.initials: A
authors.lastname: Ntinas
authors.forename: G
authors.initials: G
authors.lastname: Vergoulas
authors.forename: G
authors.initials: G
authors.lastname: Miserlis
authors.forename: F
authors.initials: F
authors.lastname: Solonaki
authors.forename: D
authors.initials: D
authors.lastname: Takoudas
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000077552:Basiliximab; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000068338:Everolimus; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012189:Retrospective Studies; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab; D000068338:Everolimus; D003404:Creatinine; D009173:Mycophenolic Acid; D020123:Sirolimus